Shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) have received an average broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating.

Zacks has also given OHR Pharmaceutical an industry rank of 101 out of 255 based on the ratings given to its competitors.

NASDAQ OHRP traded down $0.01 during trading hours on Thursday, reaching $0.18. The stock had a trading volume of 755,800 shares, compared to its average volume of 1,201,754. OHR Pharmaceutical has a 52-week low of $0.15 and a 52-week high of $2.18.

OHR Pharmaceutical (NASDAQ:OHRP) last issued its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.01) EPS for the quarter.

About OHR Pharmaceutical

OHR Pharmaceutical, Inc, a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

See Also: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on OHR Pharmaceutical (OHRP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.